1. Vor Bio sells 13.9 million shares at $10.81 each, raising $150 million. 2. Funds will advance Phase 3 trials for telitacicept in myasthenia gravis. 3. The placement includes major institutional investors like RA Capital Management. 4. Forbion gains a directorship as part of the securities purchase agreement. 5. Shares sold are unregistered under the Securities Act and rights agreements are established.
FAQ
Why Bullish?
The infusion of $150 million strengthens VOR's capital position for trials. Historical biotech fundraises often precede stock price increases, especially if trials succeed.
How important is it?
The article details significant funding that can directly lead to operational advancements, impacting share valuation.
Why Long Term?
Funding is aimed at long-term clinical development, especially for regulatory approval. Success in clinical trials can significantly elevate stock value over time.
Vor Bio Announces $150 Million Private Placement to Advance Autoimmune Disease Treatments
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases, has announced a significant private placement. The company has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share, aimed at raising approximately $150 million in gross proceeds, before expenses.
Details of the Private Placement
The agreement involves participation from a select group of institutional and accredited healthcare investors. Key participants include notable firms like RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners.
This private placement is expected to close on or about December 18, 2025, pending customary closing conditions. Notably, Forbion will also gain the right to appoint one director to Vor Bio’s board of directors as part of this transaction.
Intended Use of Proceeds
Vor Bio plans to allocate the proceeds to advance the clinical development of telitacicept, its innovative dual-target fusion protein. This includes:
- Ongoing global Phase 3 clinical trial for myasthenia gravis
- Initiation of a global Phase 3 clinical trial in primary Sjögren's disease
- General working capital and corporate purposes
Regulatory Considerations
The securities involved in this private placement have not been registered under the Securities Act of 1933 or any applicable jurisdiction’s securities laws. Consequently, shares may not be offered or sold in the United States without registration or an exemption. Vor Bio has concurrently entered into a registration rights agreement, committing to file a registration statement with the Securities and Exchange Commission for the resale of the shares issued in the private placement.
This announcement does not constitute an offer or solicitation to buy these securities in any jurisdiction where such actions would be unlawful.
About Vor Bio
Founded with a mission to transform autoimmune disease treatment, Vor Bio is at the forefront of biotechnology. The company is dedicated to advancing telitacicept through Phase 3 clinical trials to potentially address severe autoantibody-driven conditions globally. For further details, visit www.vorbio.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements pertain to Vor Bio’s expectations regarding the private placement, including expected proceeds and use of those proceeds. Vor Bio cautions investors not to place undue reliance on these forward-looking statements as actual results may differ due to various factors including market conditions and customary closing conditions.